Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting
Gain Therapeutics (NASDAQ: GANX), a clinical-stage biotech company focused on developing next-generation allosteric small molecule therapies, has announced an upcoming oral presentation at the GBA1 Meeting 2025. The event will take place from June 5th-7th in Montreal, Canada. The company's Chief Medical Officer, Dr. Jonas Hannestad, will deliver the presentation on Thursday, June 5, 2025, at 11:20 p.m. EST.
Gain Therapeutics (NASDAQ: GANX), una società biotecnologica in fase clinica specializzata nello sviluppo di terapie allosteriche di nuova generazione basate su piccole molecole, ha annunciato una presentazione orale al GBA1 Meeting 2025. L'evento si terrà dal 5 al 7 giugno a Montreal, Canada. Il Chief Medical Officer dell'azienda, Dott. Jonas Hannestad, terrà la presentazione giovedì 5 giugno 2025 alle 23:20 EST.
Gain Therapeutics (NASDAQ: GANX), una empresa biotecnológica en etapa clínica enfocada en desarrollar terapias alostéricas de próxima generación basadas en pequeñas moléculas, ha anunciado una presentación oral en el GBA1 Meeting 2025. El evento se llevará a cabo del 5 al 7 de junio en Montreal, Canadá. El Director Médico de la compañía, Dr. Jonas Hannestad, realizará la presentación el jueves 5 de junio de 2025 a las 11:20 p.m. EST.
Gain Therapeutics (NASDAQ: GANX)는 차세대 알로스테릭 소분자 치료제 개발에 주력하는 임상 단계의 바이오텍 회사로, GBA1 Meeting 2025에서 구두 발표를 할 예정임을 발표했습니다. 행사는 2025년 6월 5일부터 7일까지 캐나다 몬트리올에서 개최됩니다. 회사의 최고 의료 책임자인 Dr. Jonas Hannestad가 2025년 6월 5일 목요일 오후 11시 20분(동부 표준시)에 발표를 진행할 예정입니다.
Gain Therapeutics (NASDAQ : GANX), une société biotechnologique en phase clinique spécialisée dans le développement de thérapies allostériques de nouvelle génération à base de petites molécules, a annoncé une présentation orale lors du GBA1 Meeting 2025. L'événement se déroulera du 5 au 7 juin à Montréal, Canada. Le directeur médical de l'entreprise, Dr Jonas Hannestad, fera la présentation le jeudi 5 juin 2025 à 23h20 EST.
Gain Therapeutics (NASDAQ: GANX), ein biotechnologisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die Entwicklung neuartiger allosterischer Kleinmolekültherapien konzentriert, hat eine bevorstehende mündliche Präsentation auf dem GBA1 Meeting 2025 angekündigt. Die Veranstaltung findet vom 5. bis 7. Juni in Montreal, Kanada, statt. Der Chief Medical Officer des Unternehmens, Dr. Jonas Hannestad, wird die Präsentation am Donnerstag, dem 5. Juni 2025, um 23:20 Uhr EST halten.
- None.
- None.
BETHESDA, Md., May 29, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced an oral presentation at the GBA1 Meeting 2025, being held June 5th-7th in Montreal, Canada.
Details of the oral presentation are as follows:
Date: Thursday, June 5, 2025
Time: 11:20 p.m. EST
Presenter: Jonas Hannestad, M.D., Ph.D., Chief Medical Officer, Gain Therapeutics
About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate, GT-02287 is currently being evaluated for the treatment of Parkinson’s disease with or without a GBA1 mutation in a Phase 1b clinical trial. GT-02287 has further potential in Gaucher’s disease, dementia with Lewy bodies, and Alzheimer’s disease. Gain has multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumors.
Gain’s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced Magellan™ platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology.
Forward-Looking Statements
This release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. These forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, statements regarding: the development of the Company’s current or future product candidates including GT-02287; expectations regarding the completion and timing of results from a Phase 1b clinical study for GT-02287; expectations regarding the timing of patient enrollment for a Phase 1b clinical study for GT-02287; the timing of any submissions to the FDA or other regulatory bodies and agencies; and the potential therapeutic and clinical benefits of the Company’s product candidates. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, please refer to the Company’s Form 10-K for the year ended December 31, 2024. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.
Investors:
Gain Therapeutics, Inc.
Apaar Jammu
Manager, Investor Relations and Public Relations
ajammu@gaintherapeutics.com
LifeSci Advisors LLC
Chuck Padala
Managing Director
chuck@lifesciadvisors.com
Media:
Russo Partners LLC
Nic Johnson and Elio Ambrosio
nic.johnson@russopartnersllc.com
elio.ambrosio@russopartnersllc.com
(760) 846-9256
FAQ
When and where is Gain Therapeutics (GANX) presenting at the GBA1 Meeting 2025?
Who will be presenting for Gain Therapeutics (GANX) at the GBA1 Meeting?
What type of company is Gain Therapeutics (GANX)?
What is the duration of the GBA1 Meeting 2025 where GANX is presenting?
